Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146906 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT07146906 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT07146906, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
Interventions
- BIOLOGICAL zigakibart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2030-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146906
The ClinicalTrials.gov registry entry for NCT07146906 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zigakibart is the first listed.
NCT07146906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07146906 about?
NCT07146906 is a clinical study titled "A Study to Assess the Effects of Zigakibart on IgA Nephropathy.". The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
What is the current status of trial NCT07146906?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-03-26. Estimated completion is 2030-10-18.
What interventions are being tested in trial NCT07146906?
The interventions under investigation include: zigakibart (BIOLOGICAL).
Who is sponsoring clinical trial NCT07146906?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.